A pharmaceutical company's phase III trial for a new cholesterol medication found that patients taking the drug had an eleven percent lower rate of cardiac events than patients taking a placebo over five years, a result the company's press release described as "a clear reduction in cardiac risk." A closer reading of the trial's published data shows that the eleven percent figure describes a relative risk reduction: the absolute event rate fell from 4.2 percent in the placebo group to 3.7 percent in the treatment group, a half-point absolute difference. Because relative risk reductions can describe a large percentage change in a small absolute rate, the press release's framing, while not factually false, presents the treatment's benefit in a way likely to overstate its practical significance for any individual patient's actual risk. The trial's independent monitoring board has recommended the drug proceed to regulatory review without modification to the study protocol.